Sylvester Comprehensive Cancer Center University of Miami - Kendall

Miami, FL

Sorting 3 by

Accepting patients

MagnetisMM-20

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

MagnetisMM-5

Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)
Learn more
  • Bispecific Antibody
  • Phase 3

Accepting patients

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific T Cell Engager (BiTE)
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1
  • Has results